The purpose of this study was to examine whether exercise training reduced inflammation and symptomology in a mouse model of colitis. We hypothesized that moderate forced treadmill running (FTR) or voluntary wheel running (VWR) would reduce colitis symptoms and colon inflammation in response to dextran sodium sulfate (DSS). Male C57Bl/6J mice were randomized to sedentary, moderate intensity FTR (8-12 m/min, 40 min, 6 weeks, 5x/week), or VWR (30 days access to wheels). DSS was given at 2% (w/ v) in drinking water over 5 days. Mice discontinued exercise 24 h prior to and during DSS treatment. Colons were harvested on Days 6, 8 and 12 in FTR and Day 8 post-DSS in VWR experiments. Contrary to our hypothesis, we found that moderate FTR exacerbated colitis symptomology and inflammation as measured by significant (p < 0.05) increases in diarrhea and IL-6, IL-1b, IL-17 colon gene expression. We also observed higher mortality (3/10 died vs. 0/10, p = 0.07) in the FTR/DSS group. In contrast, VWR alleviated colitis symptoms and reduced inflammatory gene expression in the colons of DSS-treated mice (p < 0.05). While DSS treatment reduced food/fluid intake and body weight, there was a tendency for FTR to exacerbate, and for VWR to attenuate, this effect. FTR (in the absence of DSS) increased gene expression of the chemokine and antibacterial protein CCL6 suggesting that FTR altered gut homeostasis that may be related to the exaggerated response to DSS. In conclusion, we found that FTR exacerbated, whereas VWR attenuated, symptoms and inflammation in response to DSS.
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Introduction
Inflammatory bowel diseases (IBD), such as ulcerative colitis (UC), cause chronic morbidity that significantly reduce physical functioning and quality of life in afflicted patients. While UC is an idiopathic disorder, it is clear that environmental (e.g. infection, diet, psychological stress) and host genetic factors, in combination with disturbances in the intestinal microbiome, trigger barrier disruption leading to dysregulated inflammation in response to resident gut bacteria (Sanchez-Munoz et al., 2008) . Immune cell infiltration stimulates the production of pro-inflammatory cytokines, which promote a chronic inflammatory state, instigating clinical symptoms including colon ulcers, rectal bleeding, diarrhea, abdominal pain, fatigue, and an overall altered emotional well-being (Sanchez-Munoz et al., 2008) . Furthermore, UC significantly increases the risk of developing colorectal cancer later in life (Rizzo et al., 2011) .
It is well established that anti-inflammatory therapies, designed to decrease colon inflammation, attenuate the symptoms of UC in humans and mouse models of the disease (Bi and Triadafilopoulos, 2003) . Anti-inflammatory pharmaceutical treatments, such as 5-aminosalicylic acid and corticosteroids, are beneficial in reducing symptoms, but their efficacy is not complete and they have significant side-effects. Therefore, in addition to more efficacious and safer drug development, investigation of adjunct anti-inflammatory therapies that could attenuate colitis and counteract side effects of conventional treatment is of prime importance from a public health perspective. Such strategies could assist in improving the quality of life by reducing symptoms, hospitalizations, and the risk of colorectal cancer in UC patients.
Exercise has been suggested as an adjunct anti-inflammatory therapy for chronic diseases associated with inflammation (Astrom et al., 2010) . Indeed, our laboratory as well as others, have provided
